Skrining In Silico Potensi Dihidromikanolida dari Mikania micrantha Sebagai Agen Antikanker Melalui Analisis Molecular Docking

Authors

  • Faraisha Indraswari Universitas Diponegoro
  • Sania Najmi Rusydina Universitas Diponegoro
  • Kaisha Raihanuun Irsa Universitas Diponegoro
  • Shi Izumi Muthia Kamalia Universitas Diponegoro
  • Amelia Dini Hanmarizqi Universitas Diponegoro

Keywords:

Antikanker, Dihidromikanolida, Molecular docking

Abstract

Kanker merupakan masalah kesehatan global yang serius, dengan berbagai pilihan terapi saat ini, seperti kemoterapi dan radioterapi, masih menghadapi banyak hambatan, termasuk resistensi terhadap obat dan biaya pengobatan yang mahal. Kebutuhan senyawa antikanker baru yang lebih efektif menjadi hal yang krusial. Tanaman mengandung metabolit sekunder yang berpotensi sebagai kandidat obat, salah satunya adalah Mikania micrantha yang umumnya dikenal sebagai gulma invasif. Senyawa dihidromikanolida dari M. micrantha diketahui memiliki aktivitas antikanker, tetapi penelitian mengenai mekanisme molekulernya masih terbatas. Perkembangan kanker melibatkan beberapa mekanisme biologis yang diatur oleh berbagai protein, di antaranya Epidermal Growth Factor Receptor (EGFR), Cyclin-Dependent Kinase 2 (CDK2), B-cell lymphoma 2 (BCL-2), dan Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Molecular docking merupakan metode in silico untuk memprediksi interaksi antara senyawa bioaktif dan protein target yang banyak dimanfaatkan pada tahap awal penemuan obat. Penelitian ini bertujuan untuk mengevaluasi potensi dihidromikanolida dari M. micrantha sebagai kandidat antikanker melalui analisis sifat drug-likeness dan molecular docking terhadap protein EGFR, CDK2, BCL-2, dan VEGFR2. Penelitian dilakukan menggunakan website SwissADME untuk mengevaluasi sifat drug-likeness, serta software PyRx untuk melaksanakan molecular docking. Hasil analisis dengan SwissADME menunjukkan bahwa dihidromikanolida memenuhi syarat senyawa obat yang baik. Hasil molecular docking menunjukkan nilai binding affinity dari dihidromikanolida sebesar -7,4 kcal/mol terhadap EGFR; -8,9 kcal/mol terhadap CDK2; -7,5 kcal/mol terhadap BCL-2; dan -7,2 kcal/mol terhadap VEGFR2. Dihidromikanolida dinilai berpotensi sebagai antikanker yang mampu berinteraksi dengan berbagai target molekuler, dengan CDK2 sebagai target yang paling menjanjikan. Hasil penelitian ini selanjutnya dapat menjadi dasar untuk studi in vitro maupun in vivo.


ABSTRACT

Cancer is a serious global health issue with current treatment options still face many challenges, including drug resistance and high treatment costs. The need for new anticancer compounds is crucial. Plants contain secondary metabolites that have potential as drug candidates, such as Mikania micrantha, commonly known as an invasive weed. Dihydromikanolide from M. micrantha are known to possess anticancer activity, but research on its molecular mechanisms remains limited. Cancer progression involves several biological mechanisms regulated by various proteins, including Epidermal Growth Factor Receptor (EGFR), Cyclin-Dependent Kinase 2 (CDK2), B-cell lymphoma 2 (BCL-2), and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Molecular docking is an in silico method for predicting interactions between bioactive compounds and target proteins that is widely used in early stages of drug discovery. This study aims to evaluate the potential of dihydromikanolide from M. micrantha as an anticancer candidate through analysis of drug-likeness properties and molecular docking with EGFR, CDK2, BCL-2, and VEGFR2. The study was conducted using the SwissADME website to evaluate drug-likeness properties, as well as PyRx software to perform molecular docking. The results of the SwissADME analysis showed that dihydromikanolide is a good drug candidate. The docking results showed binding affinities for dihydromikanolide of -7.4 kcal/mol against EGFR; -8.9 kcal/mol against CDK2; -7.5 kcal/mol against BCL-2; and -7.2 kcal/mol against VEGFR2. Dihydromikanolide is considered to have potential as an anticancer agent, with CDK2 being the most promising target. The results of this study serve as basis for further in vitro and in vivo studies.

References

Ali Khan, M., El-Kersh, D. M., Islam, M. S., Ara Khan, S., Kamli, H., Sarkar, C., Bhuia, M. S., Islam, T., Chandra Shill, M., Gobe, G. C., Sönmez Gürer, E., Setzer, W. N., Sharifi-Rad, J., & Torequl Islam, M. (2023). Mikania micrantha Kunth: An Ethnopharmacological Treasure Trove of Therapeutic Potential. Chemistry and Biodiversity, 20(11), 35899. https://doi.org/10.1002/cbdv.202300392

Allo, V. L., Rahmah, S., & Gunawan, R. (2023). Studi Molecular Docking Senyawa Turunan Auron sebagai Inhibitor Glycoprotein Spike SARS-CoV-2. Akta Kimia Indonesia, 8(2), 126–137. http://dx.doi.org/10.12962/j25493736.v8i2.16827

Aly, R. M., Babcock, B. D., Elvin, J. A., et al. (2025). Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology, 8(1), 47–60. https://doi.org/10.36401/JIPO-24-22

Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Orhan, I. E., Banach, M., Rollinger, J. M., Barreca, D., Weckwerth, W., Bauer, R., Bayer, E. A., Majeed, M., Bishayee, A., Bochkov, V., Bonn, G. K., Braidy, N., Bucar, F., Cifuentes, A., D’Onofrio, G., Bodkin, M., & Supuran, C. T. (2021). Natural Products in Drug Discovery: Advances and Opportunities. Nature Reviews Drug Discovery, 20(3), 200–216. https://doi.org/10.1038/s41573-020-00114-z

Balch, C. M., Liao, N., Lam, D. S. C., Weitzel, J. N., Xu, R., Attard, G., & Soerjomataram, I. (2026). The Global Cancer Crisis: a Review of Growing Burden, Deepening Inequality and Initiatives for Prevention and Early Detection. Ecancermedicalscience, 20, 2071. https://doi.org/10.3332/ecancer.2026.2071

Bora, A. R., Babu, D. S., Chetry, S., & Kalita, S. (2021). Management Options of Mikania micrantha: A Review.

Agricultural Reviews, 44(Of), 393–396. https://doi.org/10.18805/ag.r-2201

Callil-Soares, Henrique, P., Biasi, Kramer, L. C., Filho, P., & Pedro de Alcântara. (2023). Effect of Preprocessing and Simulation Parameters on The Performance of Molecular Docking Studies. Journal of Molecular Modeling, 29(8), 251. https://doi.org/10.1007/s00894-023-05637-x

Cao, Y. (2017). Tumorigenesis as A Process of Gradual Loss of Original Cell Identity and Gain of Properties of Neural Precursor/Progenitor Cells. Cell & Bioscience, 7, 61. https://doi.org/10.1186/s13578-017-0188-9

Chagaleti, B. K., Nallagundla, S., Chunduri, M., Alarifi, A., Asiri, A. M., Al-Shehri, B. M., & Al-Mishari, A. A. (2025). Pyrazolopyrimidine Fused Thiazolidinone Hybrids as CDK2 Inhibitors: Insights from Pharmacophore Modeling, Molecular Docking, DFT and Molecular Dynamics Simulations. Journal of Molecular Structure, 1325, 142557. https://doi.org/10.1016/j.molstruc.2025.142557

Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717

Dhyani, P., Sati, P., Sharma, E., Attri, D. C., Bahukhandi, A., Tynybekov, B., Szopa, A., Sharifi-Rad, J., Calina, D., Suleria, H. A. R., & Cho, W.

C. (2022). Sesquiterpenoid Lactones as Potential Anti-Cancer Agents: an Update on Molecular Mechanisms and Recent Studies. Cancer Cell International, 22(1), 1–18. https://doi.org/10.1186/s12935-022-02721-9

Dipa, C.D., Hossain, S., Chy, M.M.K. (2025). In Silico Exploration of Anticancer Plant Phytochemicals for EGFR-Targeted Lung Cancer Therapy. Scientific Reports, 15, 27809. https://doi.org/10.1038/s41598-025-10412-4

Dona, R., Frimayanti, N., Ikhtiarudin, I., Iskandar, B., Maulana, F., & Silalahi, N. T. (2019). Studi In Silico, Sintesis, dan Uji Sitotoksik Senyawa P-Metoksi Kalkon terhadap Sel Kanker Payudara MCF-7. Jurnal Sains Farmasi Klinis, 6(3), 243–249.

Gyanani, V., Haley, J. C., & Goswami, R. (2021). Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems. Pharmaceuticals, 14(9), 835. https://doi.org/10.3390/ph14090835

Hartung, I. V., Huck, B. R., & Crespo, A. (2023). Rules were Made to be Broken. Nature Reviews Chemistry, 7, 3–4. https://doi.org/10.1038/s41570-022-00451-0

Karami, T. K., Hailu, S., Feng, S., Graham, R., & Gukasyan, H. J. (2022). Eyes on Lipinski's Rule of Five: A New "Rule of Thumb" for Physicochemical Design Space of Ophthalmic Drugs. Journal of Ocular Pharmacology and Therapeutics, 38(1). https://doi.org/10.1089/jop.2021.0069

Lealita, Pramesti, A. R. E. A., Rollando, & Yanuar, M. R. S. (2025). Potensi Senyawa pada Tanaman Secang (Caesalpinia sappan) dalam Menghambat Enzim COX-2 sebagai Antiinflamasi. Jurnal Farmasi Ma Chung: Sains Teknologi dan Klinis Komunitas, 3(2), 30–39. https://doi.org/10.33479/jfmc.v3i2.79

Mahardika, R. D., Rusdi, R., Ramadhan, S., Misvayanty, H., Fihandini, A., & Hakim, A. R. (2025). In Silico Screening and Molecular Docking of Potential Bioactive Compounds of Gynura divaricata as Eczema Drug Candidates. Risenologi, 10(2), 177–183. https://doi.org/10.21009/risenologi.102.07

Malik, F. K. & Guo, J. T. (2022). Insights into Protein-DNA Interactions from Hydrogen Bond Energy-Based Comparative Protein-Ligand Analyses. Proteins, 90(6), 1303–1314. https://doi.org/10.1002/prot.26313

Marques, C. S., Brandão, P., Burke, A. J. (2024). Targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2): Latest Insights on Synthetic Strategies. Molecules, 29(22), 5341. 10.3390/molecules29225341

Muhammed, M. T. & Aki-Yalcin, E. (2024). Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery. Letters in Drug Design & Discovery, 21(3), 480-495. 10.2174/1570180819666220922103109

Novianty, R. (2022). Analisis Interaksi Senyawa Guvakolin dan Homoarekolin terhadap MAO-A secara In Silico.

Jurnal Photon, 13(1), 66–73. https://doi.org/10.37859/jp.v13i1.5042

Nugroho, M. S., Danendra Daryl Abhinaya, Valensita, L., Febriana, S. I., & Fauzan, M. A. (2025). In Silico Study: Evaluation of the Potential of Turmeric Extract Curcumin as an Inhibitor Agent of Ganoderma boninense to Mitigate the Decline in CPO Production in

Indonesia. Risenologi, 10(2), 164–176. https://doi.org/10.21009/risenologi.102.06

Patel, H. D., & Patel, C. N. (2024). Advances in Synthesis and Biological Evaluation of CDK2 Inhibitors for Cancer Therapy. Bioorganic Chemistry, 143, 107045. https://doi.org/10.1016/j.bioorg.2023.107045

Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., & Wang, J. (2022). The Role of BCL-2 Family Proteins in Regulating Apoptosis and Cancer Therapy. Frontiers in Oncology, 12, 985363. https://doi.org/10.3389/fonc.2022.985363

Reynaldi, M. A., Faradilla, A., Nurbaeti, S. N., Ih, H., & Fajriaty, I. (2023). Molecular Docking Senyawa pada Komposisi Cincalok terhadap Reseptor Plasmodium Falciparum Dihydroorotate Dehydrogenase. Journal Pharmacy of Tanjungpura, 1(1), 1–12.

Rosenkranz, A. A. & Slastnikova, T. A. (2020). Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery. Biochemistry Moscow, 85, 967–993. https://doi.org/10.1134/S0006297920090011

Saragatsis, M. A., Kinsella, G. K., Curtin, J. F., & Zhang, T. (2025). Molecular Docking and Target-Specific Binding Profiles of Benzosuberane-Based Compounds. ChemMedChem, 20(21), e202500365. https://doi.org/10.1002/cmdc.202500365

Sari, I. W., Junaidin, J., & Pratiwi, D. (2020). Studi Molecular Docking Senyawa Flavonoid Herba Kumis Kucing (Orthosiphon stamineus B.) pada Reseptor α-Glukosidase sebagai Antidiabetes Tipe 2. Jurnal Farmagazine, 7(2), 54. https://doi.org/10.47653/farm.v7i2.194

Sethi, A., Joshi, K., Sasikala, K., & Alvala, M. (2019). Molecular Docking in Modern Drug Discovery: Principles and Recent Applications. Drug Discovery and Development: New Advances, 1–21.

Shah, F. H., Nam, Y. S., Bang, J. Y., Hwang, I. S., Kim, D. H., Ki, M., & Lee, H. (2025). Targeting Vascular Endothelial Growth Receptor-2 (VEGFR-2): Structural Biology, Functional Insights, and Therapeutic Resistance. Archives of Pharmacal Research, 48(5), 404–425. https://doi.org/10.1007/s12272-025-01545-1

Soares, A. C. G., Sousa, G. H. M., Calil, R. L., & Trossini, G. H. G. (2023). Absorption Matters: A Closer Look at Popular Oral Bioavailability Rules for Drug Approvals. Molecular Informatics, 42, e202300115. https://doi.org/10.1002/minf.202300115

Thalib, P. N., Kilo, A. L., Musa, W. J. A., Salimi, Y. K., Alio, L., & Aman, L. O. (2026). Studi In Silico Senyawa Methyl 4-hydroxycinnamate Sebagai Aktivator P53 pada Kanker Serviks Melalui Pendekatan Molecular Docking. Jurnal Entropi, 21(1), 58-64.

Tuan, N. D., Quoc, N. C., De, T. Q., & Khang, T. D. (2023). Step-By-Step Guide to Molecular Docking Using PyRx 0.8: Predicting Interactions of Chalcone-Amide Derivatives with SARS-CoV-2 PLpro. TNU Journal of Science and Technology, 230(1), 63–72. https://doi.org/10.34238/tnu-jst.10680

Tufféry, P., & de Vries, S. (2020). The Search of Sequence Variants Using a Constrained Protein Evolution Simulation Approach. Computational and Structural Biotechnology Journal, 18, 1790–1799. https://doi.org/10.1016/j.csbj.2020.06.018

Varela-Salinas, G., García, C., Peláez, R., & Rodríguez, A. J. (2017). Visual Clustering Approach for Docking Results from Vina and AutoDock. Lecture Notes in Artificial Intelligence, 10334, 342–353. https://doi.org/10.1007/978-3-319-59650-1_29

Veit-Acosta M, & Azevedo W. F. J. (2022). Computational Prediction of Binding Affinity for CDK2-Ligand Complexes: A Protein Target for Cancer Drug Discovery. Current Medicinal Chemistry, 29(38), 6293–6305.

Weng, M. S., Chang, J. H., Hung, W. Y., Yang, Y. C., & Chien, M. H. (2018). The Interplay of Reactive Oxygen Species and the Epidermal Growth Factor Receptor in Tumor Progression and Drug Resistance. Journal of Experimental & Clinical Cancer Research, 37, 61. https://doi.org/10.1186/s13046-018-0728-0

Zhong, J., Liu, J., Tang, X., Zhou, W., Song, G., Zeng, Y., Zhang, X., Zhou, J., JieZhou, Cao, L., Zhang, Q., & Li, Y. (2025). Cell Cycle Proteins: Linking the Cell Cycle to Tumors. Oncology Research, 33(6), 1335–1346. https://doi.org/10.32604/or.2025.058760

Downloads

Published

2026-10-31